Bio-Techne TECH
NASDAQ TECH
$72.43 -0.02 (-0.03%)
As of: Sep 4, 2026 · 12:45 PM EDT

Bio-Techne (TECH) Income from Non-Controlling Interests (2020 - 2022)

Bio-Techne (TECH) posted quarterly Income from Non-Controlling Interests of -$212000.0 for Q2 2023, down 102.29% year-over-year from $9.3 million in Q2 2022, and down 200.0% quarter-over-quarter from $212000.0 in Q4 2022.

Analysis

Bio-Techne (TECH) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends

Bio-Techne's Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at -$212000.0 for Q2 2023.

  • In Q2 2023, Income from Non-Controlling Interests fell 102.29% year-over-year to -$212000.0; the TTM figure through Jun 2023 stood at -$33000.0 (down 100.38% YoY), while the FY2023 annual figure was -$33000.0, up 52.86% from the prior year.
  • Income from Non-Controlling Interests for Q2 2023 stood at -$212000.0, down from $212000.0 in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $9.3 million in Q2 2022, with the low at -$634000.0 in Q3 2021.
  • The 4-year median for Income from Non-Controlling Interests is $32500.0 (2021), against an average of $846300.0.
  • The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests jumped 10319.1% in 2022, then plunged 102.29% in 2023.
  • Bio-Techne's Income from Non-Controlling Interests stood at $83000.0 in 2020, then fell by 20.48% to $66000.0 in 2021, then jumped by 221.21% to $212000.0 in 2022, then slumped by 200.0% to -$212000.0 in 2023.
  • Business Quant data shows TECH's Income from Non-Controlling Interests at -$212000.0 in Q2 2023, $212000.0 in Q4 2022, and -$33000.0 in Q3 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn -
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn -
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - -
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn -
8 Royalty Pharma 28.52 Bn 27.68 Bn - 63.60 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -
10 Bio-Techne 11.30 Bn 11.03 Bn 211.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 179,000.00
Jun 30, 2022 391,000.00
Mar 31, 2022 -595,000.00
Dec 31, 2021 -8.11 Mn
Sep 30, 2021 -634,000.00
Jun 30, 2021 -316,000.00
Mar 31, 2021 -380,000.00
Dec 31, 2020 -130,000.00